Diagnostic cytopathology · 2026
Cumulative Cytological Assessment of Repeated Non-Diagnostic Thyroid Fine Needle Aspirations: A Novel Approach to Reduce Diagnostic Uncertainty.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Damti Geva Shiri, Haj Wafaa Emiel, Spivak Yokhanan, Assaf Yara, Abed Al Aziz Mussa, Itzhak Daniella, Livoff Alejandro, Ronen Ohad
Аннотация
PURPOSE: Fine needle aspiration (FNA) is the primary diagnostic tool for evaluating thyroid nodules. However, 10%-21% of FNAs yield non-diagnostic (ND) results (Bethesda category I). Repeated ND findings occur in 25%-67.5% of cases, creating diagnostic uncertainty and increased healthcare costs. Our aim was to evaluate whether cumulative analysis of repeated ND cytology samples enables reclassification into a diagnostic Bethesda category.
METHODS: This retrospective observational study (2013-2024) included patients with ≥ 2 ND FNA results from the same thyroid nodule. Two blinded cytopathologists performed cumulative assessment of cellular material from consecutive ND samples to determine if reclassification into diagnostic Bethesda categories was feasible.
RESULTS: Among 1861 FNA procedures, 29 patients (1.56%) had ≥ 2 ND results. Cumulative assessment enabled reclassification in 3/29 patients (10.3%), into Bethesda category II (benign).
FINDINGS: In selected cases, cumulative cytological assessment of multiple ND FNAs may provide sufficient diagnostic material to allow reclassification. This novel cost-effective approach may help reduce diagnostic uncertainty and unnecessary procedures, and improve patient care.
METHODS: This retrospective observational study (2013-2024) included patients with ≥ 2 ND FNA results from the same thyroid nodule. Two blinded cytopathologists performed cumulative assessment of cellular material from consecutive ND samples to determine if reclassification into diagnostic Bethesda categories was feasible.
RESULTS: Among 1861 FNA procedures, 29 patients (1.56%) had ≥ 2 ND results. Cumulative assessment enabled reclassification in 3/29 patients (10.3%), into Bethesda category II (benign).
FINDINGS: In selected cases, cumulative cytological assessment of multiple ND FNAs may provide sufficient diagnostic material to allow reclassification. This novel cost-effective approach may help reduce diagnostic uncertainty and unnecessary procedures, and improve patient care.